Elanco Animal Health (NYSE:ELAN – Free Report) had its target price lifted by Morgan Stanley from $16.00 to $17.00 in a research report report published on Tuesday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock.
Several other research firms also recently commented on ELAN. BNP Paribas assumed coverage on Elanco Animal Health in a research note on Thursday, December 7th. They set an outperform rating and a $18.00 price objective for the company. Stifel Nicolaus raised Elanco Animal Health from a hold rating to a buy rating and upped their price objective for the company from $13.00 to $20.00 in a research note on Friday, January 5th. The Goldman Sachs Group upped their price objective on Elanco Animal Health from $10.00 to $12.50 and gave the company a sell rating in a research note on Wednesday, January 17th. Barclays increased their target price on Elanco Animal Health from $18.00 to $19.00 and gave the stock an overweight rating in a research note on Tuesday. Finally, TheStreet raised Elanco Animal Health from a d+ rating to a c- rating in a research note on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health currently has a consensus rating of Moderate Buy and a consensus price target of $16.71.
Check Out Our Latest Stock Analysis on Elanco Animal Health
Elanco Animal Health Stock Up 1.3 %
Shares of NYSE ELAN opened at $16.47 on Tuesday. The business has a 50-day moving average price of $15.31 and a 200 day moving average price of $12.68. The company has a quick ratio of 1.48, a current ratio of 2.82 and a debt-to-equity ratio of 0.96. The stock has a market cap of $8.12 billion, a PE ratio of -7.10 and a beta of 1.29. Elanco Animal Health has a 52-week low of $7.88 and a 52-week high of $16.88.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). The company had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1 billion. Elanco Animal Health had a negative net margin of 26.18% and a positive return on equity of 6.99%. The firm’s revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.19 earnings per share. Equities research analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.
Hedge Funds Weigh In On Elanco Animal Health
Several hedge funds have recently bought and sold shares of the company. Primecap Management Co. CA increased its stake in Elanco Animal Health by 2.9% in the 4th quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company’s stock valued at $753,945,000 after purchasing an additional 1,431,665 shares in the last quarter. Vanguard Group Inc. increased its stake in Elanco Animal Health by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock valued at $737,083,000 after purchasing an additional 467,196 shares in the last quarter. BlackRock Inc. increased its stake in Elanco Animal Health by 6.6% in the 1st quarter. BlackRock Inc. now owns 26,217,917 shares of the company’s stock valued at $684,027,000 after purchasing an additional 1,631,045 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Elanco Animal Health by 6.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 21,286,737 shares of the company’s stock valued at $317,173,000 after buying an additional 1,365,731 shares during the last quarter. Finally, Shapiro Capital Management LLC increased its position in Elanco Animal Health by 0.9% during the second quarter. Shapiro Capital Management LLC now owns 20,392,668 shares of the company’s stock worth $205,150,000 after buying an additional 188,305 shares in the last quarter. 95.29% of the stock is owned by hedge funds and other institutional investors.
Elanco Animal Health Company Profile
(Get Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Read More
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.